How do we … integrate pathogen reduced platelets into our hospital blood bank inventory?

Sara Rutter, Edward L. Snyder

Research output: Contribution to journalArticle

Abstract

For more than 50 years there has been an ongoing effort to combat transfusion-transmitted infections and provide patients with the safest possible blood. This initiative has driven much of the research within the transfusion community. Initial methods included screening donors for travel histories to banned areas and for high-risk behaviors, but pathogen-specific assays performed at the collection and manufacturing sites also have become key factors in assuring blood safety. Many of these have focused on donor and laboratory-based screening for transfusion-transmitted diseases, as evidenced by the hepatitis and human immunodeficiency virus screening in the 1970s, 1980s, and 1990s. More recently, this effort has expanded to develop donor screening assays to identify other blood-borne pathogens, such as Zika and West Nile viruses and Babesia. Bacterial contamination of units of platelets (PLTs), however, remains a significant concern. In recent years, the Food and Drug Administration has approved rapid tests to identify bacterially contaminated PLT units in the blood bank before transfusion. Other supplemental methods have been developed, however, that aim to inactivate blood-borne pathogen(s) present in the blood product, rather than to rely on our ability to identify and interdict contaminated and infected components. Pathogen reduction technology, as this is referred to, provides a proactive way to further reduce the risk posed by transfusion-transmitted infections.

Original languageEnglish (US)
Pages (from-to)1628-1636
Number of pages9
JournalTransfusion
Volume59
Issue number5
DOIs
StatePublished - May 1 2019
Externally publishedYes

Fingerprint

Blood-Borne Pathogens
Donor Selection
Blood Banks
Blood Platelets
Blood Safety
Babesia
West Nile virus
Equipment and Supplies
Aptitude
United States Food and Drug Administration
Risk-Taking
Infection
Hepatitis
Tissue Donors
HIV
Technology
Research

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Hematology

Cite this

How do we … integrate pathogen reduced platelets into our hospital blood bank inventory? / Rutter, Sara; Snyder, Edward L.

In: Transfusion, Vol. 59, No. 5, 01.05.2019, p. 1628-1636.

Research output: Contribution to journalArticle

@article{8166065a18994b0684a9cac57434efc0,
title = "How do we … integrate pathogen reduced platelets into our hospital blood bank inventory?",
abstract = "For more than 50 years there has been an ongoing effort to combat transfusion-transmitted infections and provide patients with the safest possible blood. This initiative has driven much of the research within the transfusion community. Initial methods included screening donors for travel histories to banned areas and for high-risk behaviors, but pathogen-specific assays performed at the collection and manufacturing sites also have become key factors in assuring blood safety. Many of these have focused on donor and laboratory-based screening for transfusion-transmitted diseases, as evidenced by the hepatitis and human immunodeficiency virus screening in the 1970s, 1980s, and 1990s. More recently, this effort has expanded to develop donor screening assays to identify other blood-borne pathogens, such as Zika and West Nile viruses and Babesia. Bacterial contamination of units of platelets (PLTs), however, remains a significant concern. In recent years, the Food and Drug Administration has approved rapid tests to identify bacterially contaminated PLT units in the blood bank before transfusion. Other supplemental methods have been developed, however, that aim to inactivate blood-borne pathogen(s) present in the blood product, rather than to rely on our ability to identify and interdict contaminated and infected components. Pathogen reduction technology, as this is referred to, provides a proactive way to further reduce the risk posed by transfusion-transmitted infections.",
author = "Sara Rutter and Snyder, {Edward L.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1111/trf.15241",
language = "English (US)",
volume = "59",
pages = "1628--1636",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - How do we … integrate pathogen reduced platelets into our hospital blood bank inventory?

AU - Rutter, Sara

AU - Snyder, Edward L.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - For more than 50 years there has been an ongoing effort to combat transfusion-transmitted infections and provide patients with the safest possible blood. This initiative has driven much of the research within the transfusion community. Initial methods included screening donors for travel histories to banned areas and for high-risk behaviors, but pathogen-specific assays performed at the collection and manufacturing sites also have become key factors in assuring blood safety. Many of these have focused on donor and laboratory-based screening for transfusion-transmitted diseases, as evidenced by the hepatitis and human immunodeficiency virus screening in the 1970s, 1980s, and 1990s. More recently, this effort has expanded to develop donor screening assays to identify other blood-borne pathogens, such as Zika and West Nile viruses and Babesia. Bacterial contamination of units of platelets (PLTs), however, remains a significant concern. In recent years, the Food and Drug Administration has approved rapid tests to identify bacterially contaminated PLT units in the blood bank before transfusion. Other supplemental methods have been developed, however, that aim to inactivate blood-borne pathogen(s) present in the blood product, rather than to rely on our ability to identify and interdict contaminated and infected components. Pathogen reduction technology, as this is referred to, provides a proactive way to further reduce the risk posed by transfusion-transmitted infections.

AB - For more than 50 years there has been an ongoing effort to combat transfusion-transmitted infections and provide patients with the safest possible blood. This initiative has driven much of the research within the transfusion community. Initial methods included screening donors for travel histories to banned areas and for high-risk behaviors, but pathogen-specific assays performed at the collection and manufacturing sites also have become key factors in assuring blood safety. Many of these have focused on donor and laboratory-based screening for transfusion-transmitted diseases, as evidenced by the hepatitis and human immunodeficiency virus screening in the 1970s, 1980s, and 1990s. More recently, this effort has expanded to develop donor screening assays to identify other blood-borne pathogens, such as Zika and West Nile viruses and Babesia. Bacterial contamination of units of platelets (PLTs), however, remains a significant concern. In recent years, the Food and Drug Administration has approved rapid tests to identify bacterially contaminated PLT units in the blood bank before transfusion. Other supplemental methods have been developed, however, that aim to inactivate blood-borne pathogen(s) present in the blood product, rather than to rely on our ability to identify and interdict contaminated and infected components. Pathogen reduction technology, as this is referred to, provides a proactive way to further reduce the risk posed by transfusion-transmitted infections.

UR - http://www.scopus.com/inward/record.url?scp=85065121916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065121916&partnerID=8YFLogxK

U2 - 10.1111/trf.15241

DO - 10.1111/trf.15241

M3 - Article

VL - 59

SP - 1628

EP - 1636

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 5

ER -